Source
Sickle Cell Anemia News
More recent clinical trials also show less advanced disease in patients
People with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in more recent clinical trials show less advanced disease and improved survival compared with those in earlier studies, likely reflecting early diagnosis and advances in treatment.
That’s according to a systematic review of 58 published studies covering 13 ATTR-CM clinical trials conducted between 2008 and 2022.
News Url